207 related articles for article (PubMed ID: 23645779)
1. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer.
Kawahara H; Watanabe K; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 May; 33(5):2221-5. PubMed ID: 23645779
[TBL] [Abstract][Full Text] [Related]
2. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
[TBL] [Abstract][Full Text] [Related]
3. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level.
Park IJ; Choi GS; Lim KH; Kang BM; Jun SH
Ann Surg Oncol; 2009 Nov; 16(11):3087-93. PubMed ID: 19629600
[TBL] [Abstract][Full Text] [Related]
4. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.
Ochiai H; Ohishi T; Osumi K; Tokuyama J; Urakami H; Seki S; Shimada A; Matsui A; Isobe Y; Murata Y; Endo T; Ishii Y; Hasegawa H; Matsumoto S; Kitagawa Y
Surg Today; 2012 Jan; 42(2):164-8. PubMed ID: 22075664
[TBL] [Abstract][Full Text] [Related]
5. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer.
Takagawa R; Fujii S; Ohta M; Nagano Y; Kunisaki C; Yamagishi S; Osada S; Ichikawa Y; Shimada H
Ann Surg Oncol; 2008 Dec; 15(12):3433-9. PubMed ID: 18846401
[TBL] [Abstract][Full Text] [Related]
6. [Serum anti-p53 antibodies and CEA in monitoring of recurrences of colorectal cancer].
Bielicki D; Sulzyc-Bielicka V; Domagała W
Ann Acad Med Stetin; 2008; 54(3):99-104. PubMed ID: 19839520
[TBL] [Abstract][Full Text] [Related]
7. [The clinical significance of serum anti-p53 antibody as a monitoring marker in colorectal cancer].
Amano K; Kumamoto K; Kuwabara K; Ishiguro T; Ohsawa T; Okada N; Kumagai Y; Baba H; Ishibashi K; Tsuji Y; Haga N; Ishida H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2170-2. PubMed ID: 23268013
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
9. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
Kunizaki M; Sawai T; Takeshita H; Tominaga T; Hidaka S; To K; Miyazaki T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2016 Aug; 36(8):4171-5. PubMed ID: 27466527
[TBL] [Abstract][Full Text] [Related]
10. Serum carcinoembryonic antigen levels in patients operated for colorectal carcinoma.
Veingerl B
Wien Klin Wochenschr; 2001; 113 Suppl 3():32-8. PubMed ID: 15503618
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
Kunizaki M; Fukuda A; Wakata K; Tominaga T; Nonaka T; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2017 Apr; 37(4):1979-1984. PubMed ID: 28373470
[TBL] [Abstract][Full Text] [Related]
12. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
[TBL] [Abstract][Full Text] [Related]
14. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
[TBL] [Abstract][Full Text] [Related]
15. Elevation of preoperative s-CEA concentration in stage IIA colorectal cancer can also be a high risk factor for stage II patients.
Kim CW; Yoon YS; Park IJ; Lim SB; Yu CS; Kim JC
Ann Surg Oncol; 2013 Sep; 20(9):2914-20. PubMed ID: 23760586
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer.
Park IJ; Choi GS; Jun SH
Anticancer Res; 2009 Oct; 29(10):4303-8. PubMed ID: 19846991
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K
Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063
[TBL] [Abstract][Full Text] [Related]
18. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
[TBL] [Abstract][Full Text] [Related]
19. Serum p53 antibody is a useful tumor marker of early colorectal cancer.
Noaki R; Kawahara H; Watanabe K; Ushigome T; Kobayashi S; Yanaga K
Int Surg; 2010; 95(4):287-92. PubMed ID: 21309408
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor.
Abdel-Aziz MM; Lotfy M; El-Kady IM; Abozaid M
Cancer Detect Prev; 2009; 32(4):329-35. PubMed ID: 16632243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
